Application of Parkinson’s well-being map to assess impairment of digestive system in patients of Tomsk region, Russia
Objective: The aim of this study was to evaluate results of using Parkinson's Well-Being Map (WBM) in assessment of digestive and gut dysfunction in patients…Effects of pyridostigmine bromide vs. fludrocortison in the treatment of orthostatic hypotension in Parkinson’s disease
Objective: To report results of an investigator-initiated trial to show the non-inferiority of pyridostigmine bromide (PB) vs. fludrocortisone (FC) in the treatment of symptomatic orthostatic…Parkinson’s disease prodromal dysautonomia versus pure autonomic failure and MSA
Objective: To report the long-term follow-up (10 years) of a patient with severe autonomic dysfunction as presenting symptom of Parkinson's disease (PD), analyzing the possible…Evaluation of droxidopa dosing and clinical response in 50 consecutive patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension
Objective: To determine the effect of droxidopa on clinical symptoms and standing systolic blood pressure in patients with Parkinson's disease (PD) and neurogenic orthostatic hypotention…Impact of autonomic dysfunction on disease progression and survival in Parkinson’s disease
Objective: To determine how autonomic dysfunction influences disease progression and survival in Parkinson's disease (PD). Background: Autonomic dysfunction is a common feature in PD and…Improvement in posture, pain, and cardiac autonomic function in a prospective study of osteopathic manipulative medicine and physical therapy for camptocormia in Parkinson’s disease
Objective: A prospective cohort study of the effectiveness of osteopathic manipulative medicine (OMM) and physical therapy in improving postural control and dysautonomia in Parkinson's disease…Are inflammatory bowel disease and/or treatment with aminosalicylates protective factors against Parkinson’s disease?
Objective: To analyze the association between aminosalicylate-treated inflammatory bowel disease (IBD-A) and Parkinson´s disease (PD) at population level. Background: According to the dual-hit hypothesis, the…Utilizing remote blood pressure monitoring in a phase III clinical drug trial for Parkinson’s disease
Objective: To determine the feasibility and value of remote blood pressure (BP) monitoring during a clinical trial of isradipine (a dihydropyridine calcium channel antagonist) in…Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)
Objective: To understand the characteristics of patients initiating droxidopa therapy for the treatment of neurogenic orthostatic hypotension (nOH). Background: nOH is defined as a fall…Impact of neurogenic orthostatic hypotension on healthcare utilization and costs associated with falls in Parkinson’s disease
Objective: To compare demographic and clinical characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD and neurogenic…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.